Imiquimod cream plus local radiation for skin lymphoma lesions
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage study tests whether a cancer-killing cream (imiquimod) combined with targeted local radiation can shrink and control mycosis fungoides skin lesions. It may help people whose skin lymphoma has not responded to at least one prior standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed mycosis fungoides at stage IA through IIB
- You are between 18 and 90 years old
- You have tried at least one standard treatment for mycosis fungoides and it did not work
- Your disease has been active but stable for more than 6 months
- You have at least 4 separate skin lesions, with enough total skin area involved (over 50 cm²)
- If you can become pregnant, you need a negative pregnancy test before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This trial tests a low-dose radiation treatment to the skin for early-stage mycosis fungoides, a type of lymphoma that affects the skin. The goal is to see if this treatment can help eliminate the cancer cells.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This trial tests a gel form of a drug called duvelisib that you apply directly to skin lesions. It is for people with early-stage mycosis fungoides and may help control the patches without needing whole-body treatments.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.